Hemolytic anemia is a very important immune-mediated reaction, which its late diagnosis can be fatal. Medications along with other causes can induce hemolytic anemia. Drug induced immune hemolytic anemia (DIIHA) is caused by the development of autoantibodies. Accordingly, DIIHA is rare and there is not enough data for its prevalence. Number of drugs that can cause DIIHA have increased in recent decades. A 17-year-old man who had congenital single ventricle heart (CHB) and pulmonary artery hypertension (PAH) was admitted at Imam Khomeini hospital complex affiliated to Tehran University of Medical Sciences, with chief complaint of jaundice and icter. Bosentan and Tadalafil were in the list of the drugs used by this patient. Although both drugs were recommended to be discontinued in the patient, in the course of hospitalization, the patient accidentally continued to take his Tadalafil. However, the patient’s recovery continued. Given that the patient’s Coombs test was positive, his hemolytic anemia mechanism was drug-induced immune-mediated hemolytic anemia. As a result, according to Naranjo score = 6, Bosentan was considered as the main possible culprit to induce DIIHA in this patient. Following the discontinuation of Bosentan and receiving Prednisolone, the patient’s clinical symptoms and laboratory parameters resolved and the patient was then discharged.
This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Tax calculation will be finalised during checkout.
Congenital heart block
Disseminated intravascular coagulation
Direct and indirect
Drug induced hemolytic anemia
Drug induced immune hemolytic anemia
Erythrocyte sedimentation rate
Mean cell volume
Non-steroidal anti-inflammatory drugs
Pulmonary artery hypertension
Pulmonary artery pressure
Peripheral blood smear
Red blood cell
Total iron binding capacity
White blood cell count
Kumar S, Bansal R, Bansal P, et al. Ceftriaxone-induced hemolytic Anemia: a rare case report. Perm J. 2020;24:19.088.
Garratty G. Drug-induced immune hemolytic anemia. Hematology Am Soc Hematol Educ Program. 2009;1:73–9.
Tanios GE, Doley PB, Munker R. Autoimmune hemolytic anemia associated with the use of immune checkpoint inhibitors for cancer: 68 cases from the Food and Drug Administration database and review. Eur J Haematol. 2019;102:157–62.
Garbe E, Andersohn F, Bronder E, Klimpel A, Thomae M, Schrezenmeier H, et al. Drug induced immune haemolytic anaemia in the Berlin case-control surveillance study. Br J Haematol. 2011;154:644–53.
Brodsky RA. Warm autoimmune hemolytic Anemia. N Engl J Med. 2019;381:647–54.
Stahl WM. Acute phase protein response to tissue injury. Crit Care Med. 1987;15:545–50.
Snapper I, Marks D, Schwartz L, et al. Hemolytic anemia secondary to Mesantoin. Ann Intern Med. 1953;39:619–23.
Klinger JR, Elliott CG, Levine DJ, Bossone E, Duvall L, Fagan K, et al. Therapy for pulmonary arterial hypertension in adults: update of the CHEST guideline and expert panel report. Chest. 2019;155(3):565–86.
Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30:239–45.
Elissa M, et al. Diagnosing and managing drug allergy. CMAJ. 2018;190:532–8.
Valerio C. Bosentan in the treatment of pulmonary arterial hypertension with the focus on the mildly symptomatic patient. Vasc Health Risk Manag. 2009;5:607–19.
Barst RJ, Mubarak KK, Machado RF, Ataga KI, Benza RL, Castro O, et al. Exercise capacity and haemodynamics in patients with sickle cell disease with pulmonary hypertension treated with bosentan: results of the ASSET studies. Br J Haematol. 2010;149:426–35.
Pulido T, Adzerikho I, Channick RN, et al. Macitentan and morbidity and mortality in pulmonary arterial hypertension. N Engl J Med. 2013;369:809–18.
Humbert M, Segal ES, Kiely DG, Carlsen J, Schwierin B, Hoeper MM. Results of European post-marketing surveillance of bosentan in pulmonary hypertension. Eur Respir J. 2007;30:338–44.
Gabbay E, Fraser J, McNeil K. Review of bosentan in the management of pulmonary arterial hypertension. Vasc Health Risk Manag. 2007;3:887–900.
Mylan Pharmaceuticals ULC. Product Mmonograph PrMYLAN-BOSENTAN. 2016.
Garratty G. Immune hemolytic anemia associated with drug therapy. Blood Rev. 2010;24:143–50.
Meyboom R. Intentional Rechallenge and the clinical Management of Drug-Related Problems. Drug Saf. 2013;36:163–5.
The author(s) received no financial support for the research, author-ship, and/or the publication of this article.
Conflict of interests
The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Afra, F., Mehri, M. & Namazi, S. Bosentan-induced immune hemolytic anemia in 17 years old man. A case report. DARU J Pharm Sci (2021). https://doi.org/10.1007/s40199-020-00386-1
- Drug-induced immune hemolytic anemia (DIIHA)
- Pulmonary artery hypertension (PAH)
- Hemolytic anemia
- Congenital heart block (CHB)